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tides, increased secretion occurs specifically after mRNA 
over expression  [5] . Both markers are raised in systolic 
and diastolic heart failure and correlate to echocardio-
graphic findings  [2] .
 In this issue of  Respiration , Wieshammer et al.  [6] de-
scribe the utility of NT-proBNP for pulmonologists deter-
mining if an underlying cardiac etiology exists in patients 
referred with dyspnea. In this prospective monocenter 
study conducted in the pulmonology service of an aca-
demic teaching hospital, over a 2 year period, the evalua-
tion of dyspnea of at least 2 weeks duration was performed 
using NT-proBNP as an index test. Patients underwent 
usual diagnostic testing for heart and lung disease, and as 
the examining physician was blinded to the index test, 
treatment was not changed based on NT-pro-BNP levels.
In this study, 738 patients were enrolled, 41 were excluded 
due to missing data and therefore data from 697 patients 
were available for final analysis. Cardiological findings 
were categorized into 6 groups to help in the statistical 
evaluation of the enrolled patients. The groups were as 
follows. Group 1: left ventricular hypertrophy. Group 2: 
exercise induced myocardial ischemia. Group 3: at least 
mild aortic stenosis, at least moderate mitral regurgita-
tion, severe tricuspid regurgitation without evidence of 
pulmonary hypertension, atrial septal defect or pericar-
dial effusion. Group 4: pulmonary hypertension. Group 
5: atrial fibrillation or left bundle branch block. Group 6: 
 Diagnosing the early signs of heart failure, although 
seemingly clear cut, still remains elusive in the scenario 
of acute decompensation at the level of the primary care 
physician. This is especially true in those patients with 
coexisting respiratory disorders such as chronic obstruc-
tive pulmonary disease who present with dyspnea, ‘car-
diac asthma’, or have a long history of smoking  [1, 2] . A 
vicious cycle of respiratory and right and left cardiac dis-
ease states influencing each other exists, where dyspnea 
is the common presenting symptom. A rapid screening 
method to stratify and differentiate dyspnea of  cardiac 
origin from that of a pulmonary origin is imperative for 
both the patient and the physician  [3] . 
 Biomarkers are fast becoming a reliable and widely 
used approach to determine the extent of heart failure  [4] . 
Natriuretic peptides, such as brain natriuretic peptide 
(BNP) and N-terminal fragment (NT)-proBNP are en-
dogenous peptides rapidly synthesized and secreted by 
the atrial and ventricular cardiomyocytes in response to 
myocardial stretch, raised left ventricular end diastolic 
pressure and left ventricular dysfunction  [1, 2] . BNP is an 
active hormone causing natriuresis, inhibition of the re-
nin aldosterone system, vasorelaxation, and antifibrotic, 
antihypertrophic and lusitropic effects. NT-proBNP does 
not seem to have a biological effect. BNP gene expression 
is upregulated in disease states such as congestive heart 
failure. As there are no storage granules for these pep-
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impaired left ventricular systolic function. NT-proBNP 
was found to be elevated in each of the 6 different cardio-
logical diagnoses compared to patients with no cardio-
logical findings. Sole cardiac disease was found in 5.9%, a 
combination of pulmonary and cardiac disease was found 
in 19.4%, and sole respiratory findings were seen in 59.2%. 
Furthermore, cardiac disease was found in 43.5% of pa-
tients with COPD and left ventricular systolic function 
was impaired in 8.1% of these patients.
 For the 6 cardiological groups that were created in this 
study, of which all had elevated NT-proBNP levels, the 
following standardized regression coefficients were seen: 
Group 1:   = 0.33, 95% CI 0.03–0.62, p = 0.03; group 2:
  = 0.73, 95% CI 0.11–1.35, p = 0.02; group 3:   = 0.93, 
95% CI 0.50–1.36, p  ! 0.0001; group 4:   = 1.14, 95% CI 
0.84–1.44, p  ! 0.0001; group 5:   = 1.22, 95% CI 0.90–1.53, 
p  ! 0.0001; group 6:   = 1.94, 95% CI 1.52–2.35, p  ! 0.0001 
 [6] .
 This study therefore supports and validates current 
viewpoints that the measurement of natriuretic peptides 
is beneficial not only in the emergency department, but 
also in the primary care setting as an early diagnostic test 
in cases presenting with dyspnea without an evident car-
diac etiology  [7, 8] . This finding is of great clinical rele-
vance as the vast majority of previous studies on natri-
uretic peptides were conducted in the emergency depart-
ment, while the majority of patients with dyspnea 
primarily present to doctors in private practice. The pul-
monologist benefits from a relatively rapid stratification 
as to the cause of dyspnea. This study presents a novel ap-
proach in patient diagnosis by introducing natriuretic 
peptide measurements in a nonemergency setting. This 
brings to light the fact that natriuretic peptides can indi-
cate patients with mild chronic dyspnea, thereby giving 
the primary care physician a window of opportunity to 
treat and prevent an episode of acute exacerbation. There-
fore, natriuretic peptide assessment in this setting has the 
potential to be not just an extra tool for the physician but 
an indicator that jump starts diagnosis and treatment. 
This is further supported by recent findings from a pro-
spective observational study that included consecutive 
patients with unexplained exercise intolerance referred 
for cardiopulmonary exercise testing. Elevated levels of 
BNP and NT-proBNP were found to be simple, rapid and 
accurate tools in the identification of cardiovascular lim-
itation of exercise  [9] . 
 Wieshammer et al.  [6] proposed a new use for cardiac 
biomarkers in the primary care setting. The practicality 
of this in terms of obtaining rapid lab results and then 
adjusting patient therapy is unknown. However, as pri-
mary care physicians already use laboratory tests to help 
in making diagnoses, they may be more likely to include 
natriuretic peptides into their normal diagnostic reper-
toire. It remains to be seen, however, whether primary 
care physicians will modify therapy based on these re-
sults. It is also unknown whether this will lead eventu-
ally to physicians prescribing appropriate cardiac medi-
cations that are not part of their daily routine and ensur-
ing that referrals to a cardiologist are followed through.
 Natriuretic peptide assessment is not a stand alone test 
in the setting of distinguishing cardiac from pulmonary 
dyspneas; however, it does appear to be able to lead the 
physician in the right direction and unveil underlying 
cardiac issues. The study by Wieshammer et al.  [6] helps 
to show the value of natriuretic peptides in this setting. 
Although natriuretic peptide assays are now common in 
the emergency departments of many hospitals, they are 
still foreign in primary care settings. Currently, we ben-
efit from having this test available for acutely ill patients, 
and in the future we will hopefully be able to rely on it as 
an early marker for  dyspnea of cardiac origin presenting 
in nonemergency settings.
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